#Pfizer #BioNTech #release #additional #clinical #data
- A bivalent booster dose in subjects over 55 years of age showed an approximately 4-fold increase in neutralizing antibody titres against the omicron subvariants BA.4/BA.5 compared to the original vaccine
- One month after booster vaccination with the bivalent vaccine, neutralizing antibody titres against omicron variants BA.4/BA.5 were 13.2-fold higher compared to pre-boost status in adults over 55 years of age; in adults 18 to 55 years of age, they were 9.5-fold higher compared to pre-booster titers; a booster dose of the original vaccine resulted in a 2.9-fold increase in neutralizing antibody titres in adults over 55 years of age compared to this
- The safety and tolerability profile of the Omicron BA.4/BA.5 adapted bivalent vaccine remains favorable, similar to that of the original vaccine
NEW YORK and MAINZ, Germany,…
Read on GNW: Pfizer and BioNTech release additional clinical data
